Derbend Asset Management Crispr Therapeutics Ag Transaction History
Derbend Asset Management
- $200 Million
- Q1 2024
A detailed history of Derbend Asset Management transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Derbend Asset Management holds 3,673 shares of CRSP stock, worth $155,331. This represents 0.13% of its overall portfolio holdings.
Number of Shares
3,673
Previous 3,753
2.13%
Holding current value
$155,331
Previous $234,000
6.84%
% of portfolio
0.13%
Previous 0.14%
Shares
8 transactions
Others Institutions Holding CRSP
# of Institutions
486Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$379 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$370 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$161 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$117 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$116 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.3B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....